Class information for: |
Basic class information |
| Class id | #P | Avg. number of references |
Database coverage of references |
|---|---|---|---|
| 28333 | 209 | 31.9 | 24% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 1 | 4 | ECONOMICS//EDUCATION & EDUCATIONAL RESEARCH//PSYCHOL | 3876184 |
| 320 | 3 | AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION//MEDICATION ERRORS//AMERICAN JOURNAL OF HOSPITAL PHARMACY | 39312 |
| 1464 | 2 | FOOD AND DRUG LAW JOURNAL//CONFLICT OF INTEREST//ORPHAN DRUGS | 7747 |
| 28333 | 1 | FOOD AND DRUG LAW JOURNAL//INTELLECTUAL PROPERTY PROGRAM//ADDITIONAL PATENT | 209 |
Terms with highest relevance score |
| rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|---|
| 1 | FOOD AND DRUG LAW JOURNAL | journal | 382980 | 24% | 5% | 51 |
| 2 | INTELLECTUAL PROPERTY PROGRAM | address | 194802 | 1% | 67% | 2 |
| 3 | ADDITIONAL PATENT | authKW | 146102 | 0% | 100% | 1 |
| 4 | APPROVAL REVIEW | authKW | 146102 | 0% | 100% | 1 |
| 5 | ARNOLD PUBL HLTH CANC EPIDEMIOL | address | 146102 | 0% | 100% | 1 |
| 6 | CAPPER VOLSTEAD | authKW | 146102 | 0% | 100% | 1 |
| 7 | CYRUS TANG HEMATOL PHARMACOL | address | 146102 | 0% | 100% | 1 |
| 8 | D P HYDROXYPHENYLGTYCINE | authKW | 146102 | 0% | 100% | 1 |
| 9 | DRUG PATENT | authKW | 146102 | 0% | 100% | 1 |
| 10 | EXPERIMENTAL USE EXCEPTION | authKW | 146102 | 0% | 100% | 1 |
Web of Science journal categories |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | Law | 29915 | 70% | 0% | 147 |
| 2 | Nutrition & Dietetics | 1751 | 24% | 0% | 51 |
| 3 | Food Science & Technology | 898 | 24% | 0% | 51 |
| 4 | Pharmacology & Pharmacy | 587 | 32% | 0% | 67 |
| 5 | Biotechnology & Applied Microbiology | 79 | 10% | 0% | 20 |
| 6 | Chemistry, Medicinal | 16 | 3% | 0% | 7 |
| 7 | Economics | 14 | 4% | 0% | 8 |
| 8 | Business | 8 | 1% | 0% | 3 |
| 9 | Agricultural Economics & Policy | 8 | 0% | 0% | 1 |
| 10 | Social Issues | 3 | 0% | 0% | 1 |
Address terms |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | INTELLECTUAL PROPERTY PROGRAM | 194802 | 1% | 67% | 2 |
| 2 | ARNOLD PUBL HLTH CANC EPIDEMIOL | 146102 | 0% | 100% | 1 |
| 3 | CYRUS TANG HEMATOL PHARMACOL | 146102 | 0% | 100% | 1 |
| 4 | FOLEY | 146102 | 0% | 100% | 1 |
| 5 | GOVT STRATEG GRP | 146102 | 0% | 100% | 1 |
| 6 | HOAG | 146102 | 0% | 100% | 1 |
| 7 | LAW SEOUL | 146102 | 0% | 100% | 1 |
| 8 | PATENT LITIGAT GRP | 146102 | 0% | 100% | 1 |
| 9 | PATENT PROSECUT GRP | 146102 | 0% | 100% | 1 |
| 10 | SPECIAL PROGRAM LAW OFF | 146102 | 0% | 100% | 1 |
Journals |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | FOOD AND DRUG LAW JOURNAL | 382980 | 24% | 5% | 51 |
| 2 | BIOTECHNOLOGY LAW REPORT | 121065 | 5% | 8% | 11 |
| 3 | JOURNAL OF THE PATENT AND TRADEMARK OFFICE SOCIETY | 79395 | 2% | 11% | 5 |
| 4 | ANTITRUST LAW JOURNAL | 26457 | 4% | 2% | 9 |
| 5 | COMPETITION POLICY INTERNATIONAL | 11631 | 1% | 3% | 3 |
| 6 | BIOPHARM-THE APPLIED TECHNOLOGIES OF BIOPHARMACEUTICAL DEVELOPMENT | 7423 | 1% | 2% | 3 |
| 7 | MINNESOTA LAW REVIEW | 7405 | 4% | 1% | 8 |
| 8 | RUTGERS LAW REVIEW | 3561 | 2% | 1% | 4 |
| 9 | NORTHWESTERN JOURNAL OF INTERNATIONAL LAW & BUSINESS | 3477 | 0% | 2% | 1 |
| 10 | WASHINGTON LAW REVIEW | 2639 | 2% | 0% | 4 |
Author Key Words |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | ADDITIONAL PATENT | 146102 | 0% | 100% | 1 | Search ADDITIONAL+PATENT | Search ADDITIONAL+PATENT |
| 2 | APPROVAL REVIEW | 146102 | 0% | 100% | 1 | Search APPROVAL+REVIEW | Search APPROVAL+REVIEW |
| 3 | CAPPER VOLSTEAD | 146102 | 0% | 100% | 1 | Search CAPPER+VOLSTEAD | Search CAPPER+VOLSTEAD |
| 4 | D P HYDROXYPHENYLGTYCINE | 146102 | 0% | 100% | 1 | Search D+P+HYDROXYPHENYLGTYCINE | Search D+P+HYDROXYPHENYLGTYCINE |
| 5 | DRUG PATENT | 146102 | 0% | 100% | 1 | Search DRUG+PATENT | Search DRUG+PATENT |
| 6 | EXPERIMENTAL USE EXCEPTION | 146102 | 0% | 100% | 1 | Search EXPERIMENTAL+USE+EXCEPTION | Search EXPERIMENTAL+USE+EXCEPTION |
| 7 | GENERIC BIOTECH | 146102 | 0% | 100% | 1 | Search GENERIC+BIOTECH | Search GENERIC+BIOTECH |
| 8 | INJUNCTIVE SETTLEMENTS | 146102 | 0% | 100% | 1 | Search INJUNCTIVE+SETTLEMENTS | Search INJUNCTIVE+SETTLEMENTS |
| 9 | LEXAPRO CIPRALEX | 146102 | 0% | 100% | 1 | Search LEXAPRO+CIPRALEX | Search LEXAPRO+CIPRALEX |
| 10 | LOWERING HYPOLIPIDEMIA ACTIVITIES | 146102 | 0% | 100% | 1 | Search LOWERING+HYPOLIPIDEMIA+ACTIVITIES | Search LOWERING+HYPOLIPIDEMIA+ACTIVITIES |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
| Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
|---|---|---|---|---|
| 1 | CARRIER, MA , (2014) PAYMENT AFTER ACTAVIS.IOWA LAW REVIEW. VOL. 100. ISSUE 1. P. 7 -49 | 10 | 83% | 2 |
| 2 | LIETZAN, E , POST, J , (2016) THE LAW OF 180-DAY EXCLUSIVITY.FOOD AND DRUG LAW JOURNAL. VOL. 71. ISSUE 3. P. 327 -400 | 8 | 100% | 0 |
| 3 | WANG, ZH , (2014) REANALYZING REVERSE-PAYMENT SETTLEMENTS: A SOLUTION TO THE PATENTEE'S DILEMMA.CORNELL LAW REVIEW. VOL. 99. ISSUE 5. P. 1227 -1258 | 10 | 83% | 0 |
| 4 | KOTZE, A , (2012) REINING IN PATENT TERM EXTENSIONS FOR RELATED PHARMACEUTICAL PRODUCTS POST-PHOTOCURE AND ORTHO-MCNEIL.NORTHWESTERN UNIVERSITY LAW REVIEW. VOL. 106. ISSUE 3. P. 1419-1450 | 10 | 83% | 0 |
| 5 | KELLY, C , (2011) THE BALANCE BETWEEN INNOVATION AND COMPETITION: THE HATCH-WAXMAN ACT, THE 2003 AMENDMENTS, AND BEYOND.FOOD AND DRUG LAW JOURNAL. VOL. 66. ISSUE 3. P. 417-478 | 8 | 89% | 6 |
| 6 | APEL, BT , (2015) AN ADMINISTRATIVE METER MAID: USING INTER PARTES REVIEW AND POST-GRANT REVIEW TO CURB EXCLUSIVITY PARKING VIA THE "FAILURE TO MARKET" PROVISION OF THE HATCH-WAXMAN ACT.MICHIGAN LAW REVIEW. VOL. 114. ISSUE 1. P. 107 -135 | 8 | 80% | 1 |
| 7 | GALLASCH, S , (2016) ACTIVATING ACTAVIS IN EUROPE - THE PROPOSAL OF A "STRUCTURED EFFECTS-BASED' ANALYSIS FOR PAY-FOR-DELAY SETTLEMENTS.LEGAL STUDIES. VOL. 36. ISSUE 4. P. 683 -705 | 6 | 86% | 0 |
| 8 | AVERY, M , (2008) CONTINUING ABUSE OF THE HATCH-WAXMAN ACT BY PHARMACEUTICAL PATENT HOLDERS AND THE FAILURE OF THE 2003 AMENDMENTS.HASTINGS LAW JOURNAL. VOL. 60. ISSUE 1. P. 171-+ | 7 | 78% | 6 |
| 9 | YVON, AMC , (2006) SETTLEMENTS BETWEEN BRAND AND GENERIC PHARMACEUTICAL COMPANIES: A REASONABLE ANTITRUST ANALYSIS OF REVERSE PAYMENTS.FORDHAM LAW REVIEW. VOL. 75. ISSUE 3. P. 1883-1912 | 8 | 73% | 1 |
| 10 | CARRIER, MA , (2015) EIGHT REASONS WHY "NO-AUTHORIZED-GENERIC" PROMISES CONSTITUTE PAYMENT.RUTGERS LAW REVIEW. VOL. 67. ISSUE 3. P. 697 -720 | 5 | 83% | 0 |
Classes with closest relation at Level 1 |